This clinical trial, sponsored by the University of Cambridge, evaluates the efficacy and safety of a closed-loop insulin delivery system using faster insulin aspart compared to standard insulin aspart in adults with type 1 diabetes. The study's completion in August 2020 positions it to influence market dynamics significantly, particularly in the growing segment of diabetes management technologies. The results could enhance the competitive landscape for insulin delivery systems, especially for companies focusing on advanced diabetes management solutions. Given the increasing prevalence of diabetes and the demand for improved glycemic control, successful outcomes may lead to expanded market opportunities and partnerships in the diabetes care sector.